Open an account

Tenaya Therapeutics

TNYA · NASDAQ

$0.41+$0.0324 (+8.58%)TodayMarket closed ·
Prev close $0.3776

About TNYA

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.

Employees
70
Headquarters
South San Francisco, California
Listed
Jul 30, 2021
Sector
Health Care
Industry
Biotechnology
Website
tenayatherapeutics.com

TNYA key statistics

Market cap
91.93M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.13M
Volume
3.26M
Open price
$0.3807
High today
$0.419
Low today
$0.38
52 Week high
$2.02
52 Week low
$0.3601

Tenaya Therapeutics (TNYA) at a glance

As of Oct 20, 2026, Tenaya Therapeutics (TNYA) shares are priced at $0.41, giving the company a market cap of 91.93M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.38 and $0.419. The current price is 7.9% above the day's low and 2.1% below its high.

Volume so far is 3.26M shares, below the average of 4.13M shares a day.

Over the past year Tenaya Therapeutics has ranged from $0.3601 to $2.02, and now sits 3% of the way up that range.

Tenaya Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.20 per share against an estimate of -$0.0697.

The average analyst price target is $9.52, 2221.9% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $9.52
Low
$2.02
Now
$0.41
High
$42.00

TNYA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 20.0% on average.

  1. Q3 FY24: reported -$0.30 per share against an estimate of -$0.3749
  2. Q4 FY24: reported -$0.28 per share against an estimate of -$0.3173
  3. Q1 FY25: reported -$0.24 per share against an estimate of -$0.1938
  4. Q2 FY25: reported -$0.14 per share against an estimate of -$0.255
  5. Q3 FY25: reported -$0.12 per share against an estimate of -$0.1507
  6. Q4 FY25: reported -$0.12 per share against an estimate of -$0.1237
  7. Q1 FY26: reported -$0.09 per share against an estimate of -$0.0889
  8. Q2 FY26: reported -$0.20 per share against an estimate of -$0.0697

TNYA news

  • Vandana Singh

    Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Vandana Singh

    Tenaya Therapeutics Stock Jumps After New Alnylam Deal

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Vandana Singh

    Tenaya Stock Plunges After $60 Million Equity Offering

  • Avi Kapoor

    S&P 500 Down 1%; Broadcom Earnings Top Views

  • Avi Kapoor

    Dow Rises Over 100 Points; Lululemon Posts Upbeat Q3 Earnings

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

Similar companies

Companies in the same industry as Tenaya Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.